Gilde Healthcare

Gilde Healthcare Venture&Growth portfolio company Moximed announced appointment of robert spomer as Senior Vice President of Sales. #sales #medtech #venturecapital #growthcapital #commercialization #knee #osteoarthritis Arthur Franken Pieter van der Meer Edwin de Graaf Janke Dittmer Geoff Pardo

Exciting times at Big Health! 🎉 As an investor in Big Health, Gilde Healthcare is proud to support the continued innovation in digital mental health solutions that are transforming patient care and enabling better care at lower cost. Congratulations to the Big Health team for this remarkable achievement! Janke Dittmer

Gilde Healthcare Venture&Growth portfolio company Moximed completes closing of Series D financing for $91 million to accelerate commercialization of MISHA® Knee System, an implantable shock absorber for knee osteoarthritis Pieter van der Meer Edwin de Graaf Arthur Franken #bettercareatlowercost

Excited to share the positive Phase II results of our portfolio company LEVICEPT LTD of its novel Neurotrophin-3 Inhibitor, LEVI-04, for the Treatment of Patients with Moderate to Severe Osteoarthritis! 🎉 Globally, over 600 million people have osteoarthritis (OA), making it the most common form of arthritis. Proud to be part of this important journey initiated by Simon Westbrook and funded by Medicxi, Advent Life Sciences and Gilde Healthcare To learn more about it, have a look at our press release: Pieter van der Meer Edwin de Graaf Arthur Franken Joep Muijrers Stefan Luzi, PhD Sonia Hallen Tristan Maguet Marion Pouillard Zosia van Eesteren Eliot Forster #bettercareatlowercost #osteoarthritis #venturecapital #biotech

📣 Volta Medical is thrilled to announce a joint development agreement with GE HealthCare to enhance arrhythmia procedures! Through this collaboration, we aim to integrate our #AI solution Volta AF-Xplorer™ with GE HealthCare's digital platform Prucka™ 3, and CardioLab™ EP recording system, and streamline workflows for electrophysiologists during catheter ablation procedures to treat #AFib.⚡ 🔗 Click the link to read the full press release and learn more about this initiative : https://lnkd.in/eW5VPHuF #Collaboration #Electrophysiology #AI #AtrialFibrillation #EPeeps #Innovation

We are pleased with the nomination of Real Deals ESG Awards 2024 as Impact Investor of the Year - Social. 🌟 This nomination underlines our dedication to impactful and responsible private equity investments. Investing in solutions for tomorrow's world! #GildeHealthcare #RDESGAwards #ImpactInvesting #SocialImpact #BetterCareatLowerCost

We are pleased to join the $150M financing round of CatalYm GmbH. CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is now advancing to Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy. #bettercareatlowercost #therapeutics #oncology #GDF-15 Phil L'Huillier Christine Schuberth-Wagner Eugen Leo Anne Burger Stefan Luzi, PhD Marion Pouillard Zosia van Eesteren Arthur Franken Besmire Ahmati Edwin de Graaf Geoff Pardo Joep Muijrers Pieter van der Meer Sonia Hallen Tristan Maguet Renee van der Ven

Portfolio company Eetgemak Groep becomes healthcare foodservice market leader with the acquisition of TotaalVERS   #PrivateEquity #Healthcare #Foodservice #Investments #bettercareatlowercost Hugo de Bruin Boyd Rutten Josephine Bogaerts Jelmer van der Ploeg Ludo Suykerbuyk Oksana van Vliet (Vynarchyk) Pieter van der Meer Besmire Ahmati Renee van der Ven Ronald Holtzer Jan-Pieter Ebben Gerard Hoetmer Tim de Vos Ronald van der Leer Martin van der Leer André van IJperen Onno Meijering Karlijn van der Hoeff Jaimy de Weijer RA Jody de Jong Jacoline Gortzak Eunice Bruyninckx Joyce Snijder Onno Hakvoort Oscar Janssen Ronald Braxhoofden Sander Thiadens Carlo De Haas Derk Hora Siccama Martijn Saillard Rick Voet Justin van Halst

Gilde Healthcare (#LSIEurope24 Investor) is a specialized healthcare investor managing over $2.6 billion across two fund strategies: Venture&Growth and Private Equity. The firm is headquartered in Utrecht, Netherlands with offices also in Frankfurt, Germany, and Boston, USA. In November of 2023, Gilde Healthcare announced the final close of its Gilde Healthcare Venture&Growth VI fund with €740 million in commitments. Fund VI reached the hard cap following a first close at €600 million in April 2023. The new fund focuses on fast-growing companies developing solutions for better care at lower costs. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, Medtech, and therapeutics. The new fund will invest €10-70 million per new portfolio company. The Venture&Growth fund portfolio includes companies like: • Argá Medtech SA (LSI Alumni - David Neale) • GT Medical Technologies, Inc. (LSI Alumni - Per Langoe) • Mainstay Medical (Jason Hannon) • Lumeon (Robbie Hughes) • Volta Medical (LSI Alumni - Théophile Mohr Durdez) We're excited to welcome Janke Dittmer, Susana Amorim Lopes, and Henry Zubaida from Gilde Healthcare to LSI Europe '24 this September in Sintra, Portugal. Want to see what other investors are joining us at LSI Europe ‘24? Head over to our website to see a preview of the 100 confirmed investors.

Congratulations to our portfolio company Volta Medical in presenting the positive outcome of the landmark TAILORED Atrial Fibrillation (AF) randomized controlled trial. Approximately 33 million patients worldwide are suffering from AF. Volta Medical’s artificial intelligence software solutions assist cardiac electrophysiologists during arrhythmia treatment procedures. #atrialfibrillation #healthtech #bettercareatlowercost Ariane Daney de Marcillac Arthur Franken Besmire Ahmati Christopher Allen Dirkjan B. Edward Hanlon Edwin de Graaf Geoff Pardo Henry Zubaida Janke Dittmer Joep Muijrers Karthik Bolisetty Marion Pouillard Pieter van der Meer Pommeline Korstanje Richard Wilmot Sonia Hallen Stefan Luzi, PhDi Susana Amorim Lopes Tristan Maguet Zosia van Eesteren